The Combined Company's common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "ADGM". Investors have committed to participate in the transaction in the form of $20 million in convertible debt and $22 million in equity financing.
Save time and jump to the most important pieces.
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and
Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Commercialization and Late Stage Product Development Biotechnology Company in Rare Diseases Transaction Advances Amicus Path to Profitability - Expected as of 2023 Amicus Balance Sheet Further Strengthened with a ~$200M Private Investment from Leading Biotechnology Investors Separation will Sharpen the Strategic Focus, Financial Profile, and Operational Execution of Both Companies to Address the Needs of People Living with Rare Diseases – A
Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl
Business combination transaction with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, closed on July 31, 2024 Publicly traded company renamed Adagio Medical Holdings, Inc., with Adagio Medical as an operating subsidiary Common stock expected to commence trading under ticker symbol "ADGM" on the Nasdaq Capital Market on August 1, 2024 Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD, or "ARYA IV"))), a special purpos
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and
15-12G - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
25-NSE - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
The Combined Company's common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "ADGM". Investors have committed to participate in the transaction in the form of $20 million in convertible debt and $22 million in equity financing.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1838821/000114036123016524/brhc10050928_8k.htm
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Dell Technologies (NYSE:DELL). The smallest company on a market cap basis to set a new 52-week low was Dynatronics (NASDAQ:DYNT). Everbridge (NASDAQ:EVBG)'s stock came under the most pressure, trading down 39.63% to reach a new 52-week low. Blue Ocean Acquisition (NASDAQ:BOCN) shares were the most resilient, as shares rose 0.1%, rebounding from its new 52-week low. Check out this: Insiders Buy Around $98M Of 3 Stocks These stocks set new 52-week lows on Friday: Opendoor Technologies (NASDAQ:OPEN) shares reac